Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody

References

• Pillarisetti K, Powers G, Luistro L, et al. Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv. 2020;4(18):4538–4549. doi:10.1182/bloodadvances.2020002393
   PubMed Web of Science ®Google Scholar
• European medicines agency: tecvayli (teclistamab). Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/tecvayli. Accessed December 19, 2022.
   Google Scholar
• Moreau P, Garfall AL, van de Donk NW, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495–505. doi:10.1056/NEJMoa2203478
   PubMed Web of Science ®Google Scholar
• FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma. Accessed December 18, 2022.
   Google Scholar
• Dosani T, Carlsten M, Maric I, Landgren O. The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies. Blood Cancer J. 2015;5(4):e306–e306. doi:10.1038/bcj.2015.32
   PubMedGoogle Scholar
• Swan D, Routledge D, Harrison S. The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies. Br J Haematol. 2022;196(3):488–506. doi:10.1111/bjh.17805
   PubMed Web of Science ®Google Scholar
• Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol. 2020;13(1):1–24. doi:10.1186/s13045-020-00962-7
   PubMed Web of Science ®Google Scholar
• O’Connor BP, Raman VS, Erickson LD, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 2004;199(1):91–98. doi:10.1084/jem.20031330
   PubMed Web of Science ®Google Scholar
• Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myelomaAnti-BCMA chimeric antigen receptor. Clin Cancer Res. 2013;19(8):2048–2060. doi:10.1158/1078-0432.CCR-12-2422
   PubMed Web of Science ®Google Scholar
• Verkleij CP, Frerichs KA, Broekmans M, et al. T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma. Oncotarget. 2020;11(45):4076. doi:10.18632/oncotarget.27792
   PubMedGoogle Scholar
• Garfall AL, Usmani SZ, Mateos M-V, et al. Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed and/or refractory multiple myeloma (RRMM). Blood. 2020;136:27. doi:10.1182/blood-2020-138831
   Web of Science ®Google Scholar
• Meermeier EW, Welsh SJ, Sharik ME, et al. Tumor burden limits bispecific antibody efficacy through t-cell exhaustion averted by concurrent cytotoxic therapy preclinical optimization of anti-BCMA/CD3 therapy in myeloma. Blood Cancer Discov. 2021;2(4):354–369. doi:10.1158/2643-3230.BCD-21-0038
   PubMedGoogle Scholar
• Usmani SZ, Garfall AL, van de Donk NW, et al. Teclistamab, a B-cell maturation antigen× CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021;398(10301):665–674. doi:10.1016/S0140-6736(21)01338-6
   PubMed Web of Science ®Google Scholar
• Searle E, Quach H, Wong SW, et al. Teclistamab in combination with subcutaneous daratumumab and lenalidomide in patients with multiple myeloma: results from one cohort of majesTEC-2, a Phase1b, multicohort study. Blood. 2022;140(Supplement 1):394–396. doi:10.1182/blood-2022-159711
   Google Scholar
• Rodriguez-Otero P, Dholaria B, Askari E, et al. Subcutaneous teclistamab in combination with daratumumab for the treatment of patients with relapsed/refractory multiple myeloma: results from a phase 1b multicohort study. Blood. 2021;138:1647. doi:10.1182/blood-2021-148723
   Web of Science ®Google Scholar
• Krishnan AY, Manier S, Terpos E, et al. MajesTEC-7: a Phase 3, Randomized Study of Teclistamab+ Daratumumab+ Lenalidomide (Tec-DR) versus daratumumab+ lenalidomide+ dexamethasone (DRd) in patients with newly diagnosed multiple myeloma who are either ineligible or not intended for autologous stem cell transplant. Blood. 2022;140(Supplement 1):10148–10149.
   Google Scholar
• Mazahreh F, Mazahreh L, Schinke C, et al. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood Adv. 2023;7:3069–3074. doi:10.1182/bloodadvances.2022009435
   PubMed Web of Science ®Google Scholar
• Lancman G, Parsa K, Rodriguez C, et al. Infections and severe hypogammaglobulinemia in multiple myeloma patients treated with anti-BCMA bispecific antibodies. Blood. 2022;140(Supplement 1):10073–10074. doi:10.1182/blood-2022-163733
   Google Scholar
• Sterner RM, Sakemura R, Cox MJ, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood J Am Soc Hematol. 2019;133(7):697–709.
   Google Scholar
• Trudel S, Bahlis NJ, Spencer A, et al. Pretreatment with tocilizumab prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) showed a marked reduction in cytokine release syndrome incidence and severity. Blood. 2022;140(Supplement 1):1363–1365. doi:10.1182/blood-2022-159381
   Google Scholar
• van de Donk NW, Garfall AL, Benboubker L, et al. Evaluation of prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) to inform the management of patients (pts) treated with teclistamab in MajesTEC-1. J Clin Oncol. 2023;supplement 16:8012.
   Google Scholar
• Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086–1107. doi:10.1002/ajh.26590
   PubMed Web of Science ®Google Scholar
• Bahlis NJ, Usmani SZ, Rosiñol L, et al. Matching-Adjusted Indirect Comparison (MAIC) of Teclistamab (Tec) versus Selinexor-Dexamethasone (Sel-Dex) for the Treatment of Patients (Pts) with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM). American Society of Clinical Oncology; 2022.
   Google Scholar
• Moreau P, Usmani SZ, van de Donk NW, et al. Matching-Adjusted Indirect Treatment Comparison (MAIC) of Teclistamab (Tec) versus Belantamab Mafodotin (Belamaf) for the Treatment of Patients (Pts) with Triple-Class Exposed (TCE), Relapsed/Refractory Multiple Myeloma (RRMM). American Society of Clinical Oncology; 2022.
   Google Scholar
• Pan D, Mouhieddine TH, Upadhyay R, et al. Outcomes with panobinostat in heavily pretreated multiple myeloma patients. Blood. 2022;140(Supplement 1):12483–12484. doi:10.1182/blood-2022-159806
   Google Scholar
• Goldsmith S, Fiala MA, Wang BB, et al. Bendamustine in patients with quad-and penta-refractory multiple myeloma. Blood. 2018;132:5627. doi:10.1182/blood-2018-99-112258
   Google Scholar
• Kim SJ, Bang S-M, Choi YS, et al. Bendamustine in heavily pre-treated multiple myeloma patients: results of a retrospective analysis from the Korean multiple myeloma working party. Blood Res. 2016;51(3):193–199. doi:10.5045/br.2016.51.3.193
   PubMedGoogle Scholar
• Biran N, Vesole DH, Zhang S, et al. Real-World Outcomes with Panobinostat in Patients with Penta-and Quad-Refractory Multiple Myeloma. American Society of Clinical Oncology; 2017.
   Google Scholar
• Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388(11):1002–1014. doi:10.1056/NEJMoa2213614
   PubMed Web of Science ®Google Scholar
• San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023. doi:10.1056/NEJMoa2303379
   PubMed Web of Science ®Google Scholar
• Cohen AD, Raje N, Fowler JA, Mezzi K, Scott EC, Dhodapkar MV. How to Train Your T Cells: overcoming immune dysfunction in multiple myeloma immune dysfunction and repurposing T cells in myeloma. Clin Cancer Res. 2020;26(7):1541–1554. doi:10.1158/1078-0432.CCR-19-2111
   PubMed Web of Science ®Google Scholar
• Zugmaier G, Gökbuget N, Klinger M, et al. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood J Am Soc Hematol. 2015;126(24):2578–2584.
   Google Scholar
• Osborne TR, Ramsenthaler C, Schey SA, Siegert RJ, Edmonds PM, Higginson IJ. Improving the assessment of quality of life in the clinical care of myeloma patients: the development and validation of the Myeloma Patient Outcome Scale (MyPOS). BMC Cancer. 2015;15(1):1–12. doi:10.1186/s12885-015-1261-6
   PubMedGoogle Scholar
• European Medicines Agency. Carvykti. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/carvykti. Accessed January 28, 2023.
   Google Scholar
• Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314–324. doi:10.1016/S0140-6736(21)00933-8
   PubMed Web of Science ®Google Scholar
• Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–716. doi:10.1056/NEJMoa2024850
   PubMed Web of Science ®Google Scholar
• Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an Anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2022;2022:842.
   Google Scholar
• Lin Y, Martin TG, Usmani SZ, et al. CARTITUDE-1 final results: phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma. J Clin Oncol. 2023;16:8009. doi:10.1200/JCO.2023.41.16_suppl.8009
   Google Scholar
• Hansen DK, Patel KK, Peres LC, et al. Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;16:8012. doi:10.1200/JCO.2023.41.16_suppl.8012
   Google Scholar
• Sharma S, Wang D, Lon H-K, et al. A systematic meta-analysis of cytokine release syndrome incidence in B-cell maturation antigen-targeting chimeric antigen receptor T-cell therapy and bispecific antibodies for patients with relapsed and/or refractory multiple myeloma. Blood. 2022;140(Supplement 1):10036–10038. doi:10.1182/blood-2022-169836
   Google Scholar
• Sharma N, Reagan PM, Liesveld JL. Cytopenia after CAR-T cell therapy—A brief review of a complex problem. Cancers. 2022;14(6):1501. doi:10.3390/cancers14061501
   PubMed Web of Science ®Google Scholar
• Nahas GR, Komanduri KV, Pereira D, et al. Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT). Leuk Lymphoma. 2020;61(4):940–943. doi:10.1080/10428194.2019.1697814
   PubMed Web of Science ®Google Scholar
• Thibaud S, Mia M, Van Oekelen O, et al. Comprehensive characterization of prolonged unexplained cytopenias in relapsed/Refractory Multiple myeloma patients following BCMA-Directed CAR-T cell therapy. Blood. 2022;140(Supplement 1):614–616. doi:10.1182/blood-2022-165646
   Google Scholar
• Goodman A. Patients with multiple myeloma may face CAR T-cell shortages. Availble from: https://ascopost.com/issues/september-25-2022/patients-with-multiple-myeloma-may-face-car-t-cell-shortages/. Accessed February 15, 2023.
   Google Scholar
• Kourelis T, Bansal R, Patel KK, et al. Ethical Challenges with CAR T Slot Allocation with Idecabtagene Vicleucel Manufacturing Access. American Society of Clinical Oncology; 2022.
   Google Scholar
• Kourelis T, Bansal R, Berdeja J, et al. Ethical challenges with multiple myeloma BCMA CAR-T slot allocation: a multi-institution experience. Transplant Cell Ther. 2023;29:255–258. doi:10.1016/j.jtct.2023.01.012
   PubMedGoogle Scholar
• Al Hadidi S, Szabo A, Esselmann J, et al. Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy. Bone Marrow Transplant. 2023;58(4):443–445. doi:10.1038/s41409-022-01905-1
   PubMed Web of Science ®Google Scholar
• Martin TG, Mateos MV, Nooka A, et al. Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC‐1 study of patients with relapsed/refractory multiple myeloma. Cancer. 2023;129:2035–2046. doi:10.1002/cncr.34756
   PubMed Web of Science ®Google Scholar
• Jatiani SS, Aleman A, Madduri D, et al. Myeloma CAR-T CRS management with IL-1R antagonist anakinra. Clin Lymphoma Myeloma Leuk. 2020;20(9):632–636. e631. doi:10.1016/j.clml.2020.04.020
   PubMed Web of Science ®Google Scholar
• Wong SW, Richard S, Lin Y, et al. Anakinra targeting cytokine release syndrome associated with chimeric antigen receptor T-cell therapies. Blood. 2021;138:2812. doi:10.1182/blood-2021-150592
   Web of Science ®Google Scholar
• Zhang L, Wang S, Xu J, et al. Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy. Exp Hematol Oncol. 2021;10:1–4. doi:10.1186/s40164-021-00209-2
   PubMed Web of Science ®Google Scholar
• Si S, Teachey DT. Spotlight on tocilizumab in the treatment of CAR-T-cell-induced cytokine release syndrome: clinical evidence to date. Ther Clin Risk Manag. 2020;2020:705–714.
   Google Scholar
• Nishimoto N, Yoshizaki K, Maeda K, et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol. 2003;30(7):1426–1435.
   PubMed Web of Science ®Google Scholar
• Kauer J, Hörner S, Osburg L, et al. Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies. J Immunother Cancer. 2020;8(1):e000621. doi:10.1136/jitc-2020-000621
   PubMed Web of Science ®Google Scholar
• Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24(6):739–748. doi:10.1038/s41591-018-0036-4
   PubMed Web of Science ®Google Scholar
• Wehrli M, Gallagher K, Chen Y-B, et al. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). J Immuno Can. 2022;10(1):e003847. doi:10.1136/jitc-2021-003847
   PubMed Web of Science ®Google Scholar
• Patel S, Cenin D, Corrigan D, et al. Siltuximab for first-line treatment of cytokine release syndrome: a response to the national shortage of tocilizumab. Blood. 2022;140(Supplement 1):5073–5074. doi:10.1182/blood-2022-169809
   Google Scholar
• Kenderian SS, Ruella M, Shestova O, et al. Ruxolitinib prevents cytokine release syndrome after CART cell therapy without impairing the anti-tumor effect in a xenograft model. Blood. 2016;128(22):652. doi:10.1182/blood.V128.22.652.652
   Web of Science ®Google Scholar
• Johnson TS, Terrell CE, Millen SH, Katz JD, Hildeman DA, Jordan MB. Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis. J Immunol Res. 2014;192(1):84–91. doi:10.4049/jimmunol.1302282
   Google Scholar
• Harris AH, Hohmann S, Dolan C. Real-world quality and cost burden of cytokine release syndrome requiring tocilizumab or steroids during CAR-T infusion encounter. Biol Blood Marrow Transplant. 2020;26(3):S312. doi:10.1016/j.bbmt.2019.12.389
   Web of Science ®Google Scholar
• Rees JH. Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). In: The EBMT/EHA CAR-T Cell Handbook. Springer International Publishing Cham; 2022:141–145.
   Google Scholar
• Nellan A, McCully CML, Cruz Garcia R, et al. Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques. Blood J Am Soc Hematol. 2018;132(6):662–666.
   Google Scholar
• Riegler LL, Jones GP, Lee DW. Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. Ther Clin Risk Manag. 2019;Volume 15:323–335. doi:10.2147/TCRM.S150524
   Web of Science ®Google Scholar
• Valade S, Darmon M, Zafrani L, et al. The use of ICU resources in CAR-T cell recipients: a hospital-wide study. Ann Intensive Care. 2022;12(1):75. doi:10.1186/s13613-022-01036-2
   PubMed Web of Science ®Google Scholar
• Steinbach M, Julian K, McClune B, Sborov DW. Toxicity management strategies for next-generation novel therapeutics in multiple myeloma. Ther Adv Hematol. 2022;13:20406207221100659. doi:10.1177/20406207221100659
   Web of Science ®Google Scholar
• Cohen YC, Morillo D, Gatt ME, et al. First Results from the Redirectt-1 Study with Teclistamab (Tec)+ Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). American Society of Clinical Oncology; 2023.
   Google Scholar
• Zamagni E, Boccadoro M, Spencer A, et al. MajesTEC-4 (EMN30): a phase 3 trial of teclistamab+ lenalidomide versus lenalidomide alone as maintenance therapy following autologous stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2022;140(Supplement 1):7289–7291. doi:10.1182/blood-2022-159756
   Google Scholar
• Mateos M-V, Lee JH, Manier S, Vandendries E, Benner R, Yver A. P-017: magnetisMM-7: an open label, randomized, phase 3 study of elranatamab versus lenalidomide in patients with newly diagnosed multiple myeloma who are minimal residual disease-positive after transplant. Clin Lymphoma Myeloma Leuk. 2022;22:S45. doi:10.1016/S2152-2650(22)00347-0
   Web of Science ®Google Scholar